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ABSTRACT Various types of cancer, including melanoma and non-
melanoma skin cancer, are associated with vitamin D receptor (VDR) 
polymorphisms. However, few studies have addressed VDR polymor-
phisms in patients with mycosis fungoides (MF), and previous studies 
have reported conflicting results. Aim of this case-control study was to 
assess the correlation between VDR single nucleotide polymorphisms 
(SNPs) Cdx2, Fok1, Apa1, Bsm1, and Taq1 and MF. Venous blood samples 
were collected from 41 patients with MF and 59 age- and sex-matched 
healthy controls. VDR genotypes of both groups were analyzed. Serum 
vitamin D levels of patients with MF were also analysed among varying 
stages and VDR genotypes.
Vitamin D levels were significantly low (<30 ng/mL) in 87.9% of the pa-
tients (P<0.001). No associations were found between Apa1, Cdx2, Fok1, 
and Bsm1 SNPs and MF. However, Taq1 polymorphisms were higher in 
the healthy control group (P<0.001). Our study supports the claim that 
vitamin D deficiency is common in patients with MF. On the other hand, 
our findings suggest that Taq1 polymorphisms may be associated with 
decreased susceptibility to MF. Therefore, VDRs may have complex and 
heterogeneous effects on the pathogenesis of MF.
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INTRODUCTION
Mycosis fungoides (MF) is the predominant sub-
type of primary cutaneous lymphomas (PCL) cat-
egorized as extra-nodal non-Hodgkin lymphomas. 
According to the World Health Organization (WHO) 
and European Organization of Research and Treat-
ment of Cancer (EORTC), two large PCL groups have 
been identified: cutaneous T-cell lymphomas (CTCL) 
and cutaneous B-cell lymphomas (CBCL) (1). T-cell 
lymphomas predominate in the skin and mostly pres-
ent as MF, which is a clonal expansion of CD4 positive 
(CD4+) cells (1-3).
Vitamin D is a fat soluble pro-hormone synthe-
sized by keratinocytes from 7-dehydrocholesterol 
with the induction of ultraviolet B radiation (UVR) 
or obtained from nutritional sources (vitamin D rich 
foods and supplements). Tests for circulating vita-
min D detect 25-hydroxyvitamin D (25[OH]D) or 
calcidiol (4). Calcitriol or 1,25-dihydroxyvitamin D3 
(1,25[OH]2D3), is the bioactive metabolite of the vita-
min D endocrine system (VDES) and binds the vita-
min D receptor (VDR) (5). VDES has well known effects 
on some main biological processes including serum 
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calcium concentrations, skeletal homeostasis, and 
cell proliferation and differentiation (4,6,7). Recently, 
growing evidence of functions of vitamin D on cell 
death, invasion, and metastasis has lead scientists 
to directly address the association between vitamin 
D levels, VDR polymorphisms, and skin cancer (8-10). 
VDR is activated with or without 1,25[OH]2D3 during 
hair follicle cycling and interfollicular epidermal dif-
ferentiation (IFE). Vitamin D also has potential roles in 
clearance of UVR-induced mutations in keratinocytes 
(11). Factors disrupting VDES, such as VDR deletion, 
predisposes UVR- or chemical-induced tumor forma-
tion (12,13).
To date, there have been numerous studies on 
vitamin D and non-Hodgkin lymphomas (NHL); how-
ever, conflicting results leave the exact relationship 
unclear (14-18). Distinct VDR single nucleotide poly-
morphisms (SNPs) have been found in association 
with an increased risk of lymphoma (19). Associa-
tion of poorer outcomes and 25(OH)D insufficiency 
has been suggested in patients with NHL, including 
peripheral T-cell lymphomas (20). While the role of 
VDES in NHL patients has been elucidated in recent 
years, there is a paucity of data addressing patients 
with CTCL. Recently, it has been reported that vita-
min D levels are drastically lower (<30 ng/mL) in 
76.9% of patients with CTCL (21,22). Mrotzek et al. 
reported that with sufficient serum levels of vitamin 
D, apoptosis can be induced in CTCL cells expressing 
VDR (23). Distinct VDR SNPs (Taq1, Fok1, and Bsm1) 
have been studied in patients with MF (22). Addi-
tionally, the SNPs Apa1 and Cdx2 are associated with 
lung, colorectal, prostate, and breast cancers (24-29). 
Gandini et al. presented the relevance of Taq1, Fok1, 
Bsm1, Apa1, and Cdx2 SNPs in various cancer types, 
including skin cancer (30). There is only one report of 
three SNPs (Fok1, Bsm1, and Taq1) in patients with MF 
(22). However, Cdx2 and Apa1 have not been studied 
within the context of MF. Therefore, in this study, we 
aimed to establish whether there is an association be-
tween MF and Cdx2 and Apa1 SNPs in VDR.
PATIENTS AND METHODS
Participants
This case-control study was carried out in our der-
matology clinic. Between January 2016 and Septem-
ber 2016, 41 patients (24 men, 17 women) with MF at 
various stages were recruited. The control group in-
cluded 53 age- and sex-matched healthy volunteers. 
Demographic and clinical characteristics are shown in 
Table 1. Written informed consent was obtained from 
all participants. All patients were diagnosed based 
on clinical, histopathological, immunophenotypical, 
and T-cell receptor gene rearrangement criteria. Each 
patient was staged according to the criteria of the 
EORTC (31). Patients with any known additional sys-
temic disease or patients receiving vitamin D supple-
mentation therapy were excluded.
Treatment modalities and responses of patients 
were summarized in Table 2. Definition of response 
in the skin has been performed based on modified 
Severity Weighted Assessment Tool Score (mSWAT) 
(32).
Ethics statement
This study was conducted according to the eth-
ics principles expressed in the Declaration of Helsinki 
and approved by the local ethics committee.
Samples
Serum levels of 25-hydroxyvitamin D (Roche Diag-
nostics, Mannheim, Germany) of 41 patients with MF 
and controls were analysed to investigate the asso-
ciation between disease characteristics (stage, lesion 
type, CD4/CD8, disease duration, and response to 
treatment) and baseline vitamin D levels. A competi-
tive electrochemiluminescence protein assay (Roche 
Diagnostics, Mannheim, Germany) was performed to 
determine serum vitamin D levels. Values of less than 
30 ng/mL and 20 ng/mL were considered vitamin D 
insufficient and deficient, respectively. Patients with 
low levels of vitamin D were treated with appropriate 
supplementation. Venous blood samples (5 mL) of 
patients and controls were drawn to determine VDR 
SNP polymorphisms. 
Analysis of polymorphisms
Cdx2 (rs11568820), Fok1 (rs2228570), Bsm1 
(rs1544410), Apa1 (rs11168271), and Taq1 (rs731236) 
variants were analysed with the SNaPshot® Multiplex 
System (Applied Biosystems, Life Technologies, USA) 
using primers designed in-house. Fragment analysis 
was performed on an ABI 3130 Genetic Analyzer (Ap-
plied Biosystems). GeneMapper® Software version 
4.0 (Applied Biosystems) was used for data analysis. 
Statistical analysis
All statistical calculations were performed using 
the IBM Statistical Package for the Social Sciences 
(SPSS; SPSS Inc., Chicago, IL, USA) 21 for Windows. 
Data are given as mean ± Standard Deviation (SD) 
or median and interquartile range. Categorical vari-
ables are presented as frequencies or percentage. 
Categorical data were compared using Chi square (χ2) 
or Fischer tests. Mann–Whitney U test was performed 
for comparing numerical data of groups. Spear-
man’s correlation test was used to assess correlation 
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between categorical variables. Multiple logistic re-
gression analyses were adjusted for analyzing the ad-
ditive model effect of genotype distribution. Effects 
of dominant and recessive models were analysed 
by χ2. Associations between disease and genotypes 
were assessed by calculating odds ratios and 95% 
confidence intervals. Determination of allele frequen-
cies was performed according to the Hardy-Weinberg 
model. P values <0.05 were considered statistically 
significant.
Table 1. Baseline demographic and clinic charac-




Sex Male 24 (58.5)
Female 17 (41.5)
Disease duration months)* 50.5 (1-360)












Total body surface area µ 6.2 (1-26)
CD4/CD8¥ 1.86 (0.6-4)
Family history for MF 2 (4.9)
*Data presented as mean ± Standard Deviation, n: number, 
%: percentage
µ Mean percentage of the involvement and range are pre-
sented.
MF: mycosis fungoides; TNM: tumor node metastasis.
Table 2. Treatments of the patients with MF and  
responses to therapy
Treatment Modality n (%)
Topical* 11 (26.0)
Bexarotene gel 1 (2.4)
Narrowband UVB 20 (28.8)
PUVA 1 (2.4)
IFN+systemic retinoid 3 (7.3)
Methotrexate + retinoid 1 (2.4)






*Topical treatment included emollients and topical ste-
roids.
±Treatment responses were evaluated according to 
the modified Severity Weighted Assessment Tool Score 
(SWAT).
RESULTS
The mean age of all patients was 54.2±13.3 years 
with a range of 22-84. The mean disease duration was 
50.5 months.
Among all MF cases studied, the mean serum 
25(OH)D level was 19.2±11.44 ng/mL. Levels of 
25(OH)D were similar among male (15, 19) and female 
patients (19, 29). Vitamin D insufficiency was observed 
in 88% of subjects, whereas 63% were deficient (<20 
ng/mL). The median and mean 25(OH) D levels were 
significantly lower compared with controls (P=0.039).
Primary MF lesion, BSA, disease duration, stage, 
CD4/CD8 rates, and response to treatments were 
not correlated with 25(OH)D vitamin levels and VDR 
polymorphisms. Vitamin D levels were not associated 
with relevant VDR polymorphisms.
The mutant allele frequencies of Cdx2, Fok1, Bsm1, 
Apa1, and Taq1 and relevant nucleotide changes 
are presented in Table 3. There was no difference 
Table 3. SNPs of VDR, nucleotide changes and allele frequencies of the Turkish population
SNP # RFLPαname dbSNP∞ AA change Gene Wild type Mutant MAFµ (%)
1 Cdx2 rs11568820 - VDR G A 42
2 FokI rs2228570 M1T VDR C T 35
3 BsmI rs1544410 - VDR G A 27
4 ApaI rs11168271 - VDR G T 50
5 TaqI rs731236 - VDR C T 26
α Restriction Fragment Length Polymorphism
∞The single nucleotide polymorphism database
µMutant allele frequency
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Table 4. SNPs of VDR among MF and control groups (CI; confidence interval)








 Normal 67.9 (36) 56.1 (23) 1 (ref ) 0.498
 Heterozygous 22.6 (12) 31.7 (13) 0.59 (0.23-1.51)
 Homozygous 9.4(5) 12.2 (5) 0.63 (0.16-2.45)
FokI C/T polymorphism
 Normal 49.1 (26) 56.1 (23) 1 (ref ) 0.128
 Heterozygous 41.5 (22) 43.9 (18) 1.28 (0.34-2.17)
 Homozygous 9.4 (5) 0.0 (0) -
BsmI G/A polymorphism
 Normal 39.6 (21) 43.9 (18) 1 (ref ) 0.881
 Heterozygous 45.3 (24) 43.9 (18) 1.14 (0.47-2.78)
 Homozygous 15.1 (8) 12.2 (5) 1.37 (0.38-4.94)
ApaI G/T polymorphism
 Normal 43.4 (23) 34.1 (14) 1 (ref ) 0.191
 Heterozygous 28.3 (15) 46.3 (19) 0.48 (0.18-1.24)
 Homozygous 28.3 (15) 19.5 (8) 1.1 (0.38-3.37)
TaqI C/T polymorphism
 Normal 17.0 (9) 51.2 (21) 1 (ref )
<0.001
0.081
 Heterozygous 47.2 (25) 39.0 (16) 0.090 (0.024-0.34)
 Homozygous 35.8 (19) 9.8 (4) 0.32 (0.094-1.14)
in polymorphisms between groups. However, Taq1 
polymorphisms were significantly more frequent in 
the control group (P<0.001) (Table 4). Each allele was 
protective for MF (OR: 3.4 with 95% confidence inter-
val). The Taq1 polymorphism was associated with sta-
tistically significant reduction in risk in the recessive 
model (OR: 5.2 with 95% confidence interval) and the 
dominant model (OR: 5.1 with 95% confidence inter-
val). We could not detect a significant Taq1 polymor-
phism among clinical and laboratory characteristics 
including lesion type, duration of disease, family his-
tory, stage, CD4/CD8, 25(OH) D vitamin levels, and 
treatment responses.
DISCUSSION
Insufficiency of vitamin D is associated with high-
er rates of malignancies and autoimmune diseases, 
and many reports suggest a chemopreventive role 
of vitamin D in distinct malignancies (33-35). Fur-
thermore, previous reports have addressed vitamin D 
status and VDR genotypes of patients with NHL, but 
the results were conflicting. Most studies found no 
relationship between vitamin D levels and NHL risk 
(36-38). A recent meta-analysis by Lu et al. supports 
these findings (18). Most of the studies regarding VDR 
genotypes (Taq1 and Fok1) of patients with NHL have 
failed to demonstrate an association of these SNPs 
with overall risk of NHL (39,40). 
Vitamin D is an important determinant in the 
differentiation of CD4+ T-cells (41). In various cancer 
types, 1,25 D acts via VDR to inhibit proliferation and 
induce apoptosis of malignant clones (42). T-cells ex-
press functional VDR, and activated T-cells have the 
capacity to produce 1,25(OH)2D3 from 25(OH)D (43). 
Mrotzek et al. recently addressed whether vitamin D 
controls malignant T-cell clones and demonstrated 
that with sufficient serum vitamin D levels, CTCL line 
cells expressing VDR are induced to undergo apopto-
sis (23). These reports emphasize the importance of 
VDR gene analyses in patients with CTCL.
However, there is limited data regarding the ef-
fects of vitamin D levels and VDR gene SNPs in pa-
tients with CTCL. Recently, Talpur et al. reported low 
levels of 25(OH)D in a large proportion of patients 
with CTCL and that correction of the deficiency and 
type of supplementation did not affect the overall 
response (21). Similarly, our current study supports 
a high prevalence of vitamin D deficiency in patients 
with CTCL (66%). However, we did not detect an in-
verse correlation of vitamin D levels and involved 
BSA of patients with MF. Of note is that there was no 
relationship between baseline vitamin D levels and 
other clinical characteristics. Indeed, not surprisingly, 
patients with low levels who took the supplementa-
tion therapy and patients with sufficient 25(OH) D 
levels at initial presentation showed similar therapy 
responses.
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A previous study reported that vitamin D levels 
were significantly lower and the CC phenotype of 
the Fok1 polymorphism  more frequent in patients 
than controls (22). We found no evidence of asso-
ciation with Bsm1, Fok1, Apa1, and Cdx2 genotypes. 
However, the Taq1 polymorphism was detected more 
frequently (83%) in the healthy control group, where-
as it was 26% in the MF group. These data suggest 
that Taq1 genotype may be protective against CTCL 
in the Turkish population. The observed differences 
between studies may be related to different popula-
tions, because MF has a multifactorial etiopathogen-
esis involving complex interactions between heri-
table factors and environmental factors. Our finding 
that there was no significant correlation between 
VDR SNPs and disease duration, family history, clini-
cal characteristics, and treatment responses is similar 
to previous reports. 
Our study primarily addressed the relationship 
between VDR SNPs and MF. To the best of our knowl-
edge, this report provides the first analysis of Apa1 
and Cdx2 SNPs in patients with MF. 
CONCLUSION
In this study, we detected low baseline vitamin D 
levels in patients with MF irrespective of clinical char-
acteristics including family history, stage, TBSA, CD4/
CD8 ratio, and treatment responses. Notably, among 
five SNPs, Taq1 was more frequent (83%) in the con-
trol group, suggesting a potential preventive effect 
on the development of CTCL. However, it is not pos-
sible to make strong conclusions on VDR polymor-
phisms in patients with MF based on this study alone. 
Large epidemiologic studies are needed to provide 
better understanding of the exact role of VDES and 
VDR genotypes in MF pathogenesis.
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